As Per the Report, the Europe Lidocaine Ointment Market Size is valued at USD xx Million in 2020 and is poised to reach USD xx Million by 2025, to grow at a CAGR of xx.x% during the forecast period 2020-2025.
Lidocaine is a medicinal drug used to numb tissues. It is also known as xylocaine and lignocaine. Lidocaine blocks sodium channels and thus local neurons cannot signal the brain. It is used to relieve pain and irritation caused due to insect bites, minor cuts, sore mouth, and sunburn, etc.
The significant drivers are increasing the use of lidocaine ointment in the cosmetic industry for pain relief and growing demand for lidocaine ointment as an anti-itching and pain relief medicine for insect bites, burns, skin scrape, and minor cuts, etc. Increasing R&D, rise in disposable income and growing awareness is also expected to drive the market over the forecast period. Strict regulations regarding the safety and efficacy of the lidocaine ointment are major restraints limiting this industry.
Europe Lidocaine Ointment Market segmented and sub-segmented into the following categories
On the basis of region, Europe is assumed as a developed market and is anticipated to witness significant growth in the forecast period.
Promising Companies dominating the Europe Lidocaine Ointment Market Profiled in the Report are AstraZeneca Plc., Glenmark Pharmaceuticals, Teligent, Inc., Proficient Rx LP, ., Septodont Healthcare India Pvt. Ltd., Gemini Pharmaceuticals, Amneal Pharmaceuticals LLC, Taro Pharmaceuticals U.S.A. Inc., Novocol Inc. and Centura Pharmaceuticals, Inc.,
1. Introduction
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2. Research Methodology
2.1 Introduction
2.2 Research Phases
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Econometric Modelling
2.2.4 Expert Validation
2.3 Analysis Design
2.4 Study Timeline
3. Overview
3.1 Executive Summary
3.2 Key Inferences
3.3 Epidemology
4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5. Market Segmentation
5.1 Formulation
5.1.1 Introduction
5.1.2 Internal Use
5.1.3 Topical Use
5.1.4 Y-o-Y Growth Analysis, By Formulation
5.1.5 Market Attractiveness Analysis, By Formulation
5.1.6 Market Share Analysis, By Formulation
5.2 Application
5.2.1 Introduction
5.2.2 Cosmetics
5.2.3 Medical
5.2.4 Others
5.2.5 Y-o-Y Growth Analysis, By Application
5.2.6 Market Attractiveness Analysis, By Application
5.2.7 Market Share Analysis, By Application
6. Geographical Analysis
6.1 Introduction
6.1.1 Regional Trends
6.1.2 Impact Analysis
6.1.3 Y-o-Y Growth Analysis
6.1.3.1 By Geographical Area
6.1.3.2 By Formulation
6.1.3.3 By Application
6.1.4 Market Attractiveness Analysis
6.1.4.1 By Geographical Area
6.1.4.2 By Formulation
6.1.4.3 By Application
6.1.5 Market Share Analysis
6.1.5.1 By Geographical Area
6.1.5.2 By Formulation
6.1.5.3 By Application
6.2 U.K
6.3 Spain
6.4 Germany
6.5 Italy
6.6 France
6.7 Rest of Europe
7. Strategic Analysis
7.1 PESTLE analysis
7.1.1 Political
7.1.2 Economic
7.1.3 Social
7.1.4 Technological
7.1.5 Legal
7.1.6 Environmental
7.2 Porter’s Five analysis
7.2.1 Bargaining Power of Suppliers
7.2.2 Bargaining Power of Consumers
7.2.3 Threat of New Entrants
7.2.4 Threat of Substitute Products and Services
7.2.5 Competitive Rivalry within the Industry
8. Market Leaders' Analysis
8.1 AstraZeneca Plc.
8.1.1 Overview
8.1.2 Product Analysis
8.1.3 Financial analysis
8.1.4 Recent Developments
8.1.5 SWOT analysis
8.1.6 Analyst View
8.2 Centura Pharmaceuticals, Inc.
8.3 Amneal Pharmaceuticals LLC
8.4 Gemini Pharmaceuticals, Inc.
8.5 Glenmark Pharmaceuticals
8.6 Novocol Inc.
8.7 Proficient Rx LP
8.8 Septodont Healthcare India Pvt. Ltd.
8.9 Taro Pharmaceuticals U.S.A., Inc.
8.10 Teligent, Inc.
9. Competitive Landscape
9.1 Market share analysis
9.2 Merger and Acquisition Analysis
9.3 Agreements, Collaborations, and Joint Ventures
9.4 New Product Launches
10. Market Outlook and Investment Opportunities
Appendix
a) List of Tables
b) List of Figures
Related Reports
Feb 2020
